At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 413 enrolled
Drug / intervention
FluBlok +3 morebiological
Likely dose
FluBlok 5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of CD4 T Cell Induction and Antibody Responses Between a Pure Hemagglutinin Influenza Vaccine and Licensed Subvirion Influenza Vaccine Made in Eggs or Cell Culture in Healthy Adults.
In Brief
A Phase 4 clinical trial evaluating FluBlok, Fluzone, and 2 other interventions for Influenza. Completed, enrolled 413 participants across 1 site.
Detailed Summary
This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedMar 2017
Primary CompletionJun 2020
Study CompletionJun 2021
TodayJul 2026
First PostedMar 3, 2017
Enrollment StartOct 28, 2015
Primary CompletionJun 30, 2020
Study CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 9.3 years ago
Interventions
FluBlokbiological
FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
Fluzonebiological
Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
FluCelVaxbiological
FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
Fluzone HDbiological
Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly